Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Egg-Freezing showdown: tamoxifen vs letrozole for breast cancer patients

NCT ID NCT03011684

Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether tamoxifen or letrozole works better for preserving fertility in women with estrogen-sensitive breast cancer before starting chemotherapy. About 309 participants will take one of the two drugs during ovarian stimulation to freeze their eggs. The main goal is to see which drug leads to more mature eggs retrieved.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tamoxifen and letrozole (oral drugs)
What this could lead to
If it works, this could help doctors choose the best drug to maximize egg yield for fertility preservation in breast cancer patients.
What could go wrong
This trial is still recruiting and results are not yet available. The drugs may not differ significantly in egg yield, and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 309 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2016

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * New breast cancer diagnosis * Has not yet begun chemotherapy * Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment * Age 18 years old or greater Exclusion Criteria: * Chemotherapy has already commenced or been completed * History of recurrent breast cancer (with a prior history of chemotherapy) * Stage IV breast cancer diagnosis (metastases remote from the breast) * Patient's oncologist advises against the trial - in which case they can choose to receive stimulation with letrozole+gonadotropin * Does not plan to undergo ovarian stimulation and oocyte retrieval prior to diagnosis * Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow-up, or interpretation of study results * Age less than 18 years old

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Estrogen-receptor-positive breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California at San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.